<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05797220</url>
  </required_header>
  <id_info>
    <org_study_id>E-10840098-772.02-786</org_study_id>
    <nct_id>NCT05797220</nct_id>
  </id_info>
  <brief_title>Effect of Additional Topical Diltiazem on Botulinum Toxin Injection for Chronic Anal Fissure</brief_title>
  <official_title>Effect of Additional Topical Diltiazem on Botulinum Toxin Injection for Chronic Anal Fissure: Retrospective Analysis of 217 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul Medipol University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul Medipol University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anal fissure (AF) is a painful tear extending from the anal canal to the dentate line.&#xD;
      Although the exact pathophysiology is not known, an increase in anal tonus, decreased&#xD;
      ano-dermal blood flow and local ischemia are possible mechanisms. The most effective&#xD;
      treatment modality in chronic AF is lateral internal sphincterotomy however, incontinence&#xD;
      rates are still reported as high as 8-30%. Topical diltiazem and botulinum toxin (BT)&#xD;
      injection are good alternatives to surgery with lack of persistent side effects, easy&#xD;
      applicability, and reproducibility, however, recurrence rates were reported up to 50% for&#xD;
      each. A combination of BT with topical diltiazem may provide better results in terms of&#xD;
      healing and recurrence. In this retrospective analysis a comparison of BT injection alone and&#xD;
      BT injection combined with topical diltiazem treatment was performed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 4, 2016</start_date>
  <completion_date type="Actual">June 30, 2022</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fissure healing at 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>Evaluation of complete epithelization of the fissure by the principal investigator by rectal examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Any recurrent symptoms reported by the patient at phone call follow-up</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">217</enrollment>
  <condition>Anal Fissure Chronic</condition>
  <arm_group>
    <arm_group_label>Botulinum toxin group</arm_group_label>
    <description>The procedures were performed at outpatient clinic without anesthesia. Lyophilized 100 IU BT Type-A (BOTOX, Alergan, CA, USA) was applied after diluted with 1 cc saline. A 26-G injector was used to inject 25 unit toxin in every 4 quadrants, to the alignment of clock 12, 3, 6, and 9 to internal anal sphincters.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botulinum toxin plus topical diltiazem group</arm_group_label>
    <description>The procedures were performed at outpatient clinic without anesthesia. Lyophilized 100 IU BT Type-A (BOTOX, Alergan, CA, USA) was applied after diluted with 1 cc saline. A 26-G injector was used to inject 25 unit toxin in every 4 quadrants, to the alignment of clock 12, 3, 6, and 9 to internal anal sphincters. After BT injection, topical 2% diltiazem gel was prescribed, applied 2 times per day for 10 days (2 doses of 1 gr each per day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A Injection [Botox]</intervention_name>
    <arm_group_label>Botulinum toxin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A Injection [Botox] + Diltiazem Hydrochloride 20 Mg/G Rectal Gel</intervention_name>
    <arm_group_label>Botulinum toxin plus topical diltiazem group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Female and males older than 18 years old&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with complaints longer than 8 weeks (chronic anal fissure)&#xD;
&#xD;
          -  Patients who completed 24 months of follow-up (3rd day, 10th day, and 2nd-month&#xD;
             face-to-face clinic visits and 6, 12, and 24 months phone calls)&#xD;
&#xD;
          -  Patients who received conservative treatments including topical diltiazem and nitrites&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with previous anal surgery (lateral internal sphincterotomy,&#xD;
             hemorrhoidectomy, anal fistula)&#xD;
&#xD;
          -  Patients with inflammatory bowel diseases&#xD;
&#xD;
          -  Patients with accompanying anorectal disease (hemorrhoids, anal fistula, abscess)&#xD;
&#xD;
          -  Patients who underwent botulinum toxin injection within 1 year before recruitment&#xD;
&#xD;
          -  Patients with anterior, lateral, or multiple fissures&#xD;
&#xD;
          -  Comorbidities (AIDS, sexually transmitted disease, tuberculosis, leukemia)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Prescription of calcium canal blockers or nitrites&#xD;
&#xD;
          -  Hypersensitivity to diltiazem or botulinum toxin&#xD;
&#xD;
          -  Patients without anal pain&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Naciye Cigdem Arslan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medipol University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medipol Bahcelievler Hospital</name>
      <address>
        <city>Istanbul</city>
        <state>Other (Non U.s.)</state>
        <zip>34196</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>October 4, 2022</study_first_submitted>
  <study_first_submitted_qc>April 3, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2023</study_first_posted>
  <last_update_submitted>April 3, 2023</last_update_submitted>
  <last_update_submitted_qc>April 3, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>botulinum toxin, anal fissure, diltiazem</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fissure in Ano</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diltiazem</mesh_term>
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

